LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
LOTTE Biologics signs its first commercial manufacturing deal for Songdo Plant 1, with 120,000L capacity and 2027 production start, strengthening its globa
Research Desk
LOTTE Biologics announced that it has signed a commercial manufacturing agreement with a global pharmaceutical company whose identity was not disclosed.
Under the deal, the company will provide integrated drug substance and drug product manufacturing services for key products in the customer's portfolio, with commercial production targeted to begin in 2027.
LOTTE Biologics Secures First Major Deal
The agreement is the first major commercial manufacturing commitment secured for Songdo Plant 1, located at the company's Songdo Bio Campus, and it was finalized before the facility has begun operations.
LOTTE Biologics, which is led by Co-CEOs James Park and Yoo-yeol Shin, presents the pre-launch deal as evidence of customer confidence in its technical expertise, execution capabilities, and long-term supply reliability.
Songdo Plant 1 and the Wider Campus Build-Out
Songdo Plant 1 will provide 120,000 liters of biomanufacturing capacity through eight 15,000-liter stainless-steel bioreactors.
The facility is equipped with state-of-the-art production infrastructure, advanced automation, and large-scale cold-chain warehousing that the company says will support efficient, reliable, and quality-driven operations. The plant is the first stage of a broader development at the Songdo Bio Campus, which is planned to reach a total capacity of 360,000 liters across three plants.
LOTTE Biologics states that by aligning its capacity expansion with customer commitments from the outset, it is accelerating its path to commercialization and establishing a foundation for sustainable growth.
Syracuse Operations Form the Other Half of a Two-Site Network
The Songdo site will work alongside the company's established Syracuse Bio Campus in New York. According to LOTTE Biologics, the Syracuse site has more than two decades of manufacturing experience and has supported over 62 regulatory approvals.
The site also recently completed a US Food and Drug Administration inspection with zero observations. The company describes the two campuses together as an integrated global manufacturing network designed to deliver operational flexibility, consistent quality standards, and greater supply chain resilience.
Deal Framed Against Industry Demand for Diversified Supply
LOTTE Biologics situates the agreement within broader industry dynamics, noting that pharmaceutical companies are increasingly seeking trusted manufacturing partners with proven execution capabilities and geographically diversified supply networks.
The company positions the deal as a tangible step toward its ambition of becoming a compelling partner for global biologics manufacturing and building a differentiated global contract development and manufacturing organization.
Co-CEO Points to Combined Strength of Syracuse and Songdo
James Park, Co-CEO of LOTTE Biologics, said in the announcement, "This agreement is a strong endorsement of our strategy and the confidence our customers place in LOTTE Biologics. We are not simply building manufacturing capacity. We are building a globally integrated platform designed to deliver quality, reliability, and speed. By combining Syracuse's proven expertise with Songdo's advanced infrastructure, we are well positioned to support our partners' success and bring life-changing medicines to patients worldwide."
What is Confirmed So Far
What is confirmed about the new engagement is its scope, integrated drug substance and drug product manufacturing for key products in the customer's portfolio, and its timeline, with commercial production targeted for 2027, the year after the agreement was signed.
With the commitment in place before Plant 1 begins operations, the Songdo Bio Campus enters its launch phase with anchored demand, while the company characterizes the agreement as validation of its strategy and a step in building a globally integrated platform pairing its New York operations with its new South Korean site.
Tracked in the database
Contract Manufacturing / CDMO Expansion · Asia-Pacific
Contract Manufacturing / CDMO Expansion
Asia-Pacific
Chemical
17 November 2026
3 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
Johnson & Johnson Acquires Ollin Biosciences for $2.2 Billion to Advance Phase 3 Retinal Drug in the US
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.